Cited by 179Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 170 of the 175 references it cites were found in a registry or an index.

Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies

Abi-Dargham, Anissa, Laruelle, Marc·2005·European Psychiatry

Abstract

Multiple lines of evidence including recent imaging studies suggest that schizophrenia is associated with an imbalance of the dopaminergic system, entailing hyperstimulation of striatal dopamine (DA) D2 receptors and understimulation of cortical DA D1 receptors. This DA endophenotype presumably emerges from the background of a more general synaptic dysconnectivity, involving alterations in N-methyl-d-aspartate (NMDA) and glutamatergic (GLU) functions. Equally important is the fact that this DA dysregulation might further impair NMDA transmission. The first generation antipsychotic (FGA) drugs are characterized by high affinity to and generally high occupancy of D2 receptors. The efficacy of FGAs is limited by a high incidence of extrapyramidal side-effects (EPS). Second generation antipsychotic (SGA) drugs display reduced EPS liability and modest but clinically significant enhanced therapeutic efficacy. Compared to FGAs, the improved therapeutic action of SGAs probably derives from a more moderate D2 receptor blockade. We will review the effects of SGAs on other neurotransmitter systems and conclude by highlighting the importance of therapeutic strategies aimed at directly increasing prefrontal DA, D1 receptor transmission or NMDA transmission to enhance the therapeutic effect of moderate D2 receptor antagonism.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.eurpsy.2004.11.003

Cites

170 of 170 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 175 references

5 of the 175 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. Lindvall, 1983, Chemical neuroanatom, 229
  2. Kolachana, 1996, Abnormal prefrontal cortical regulation of striatal dopamine release after neonatal medial temporal-limbic lesions in rhesus monkeys, Soc Neurosci
  3. Weinberger, 2001, Neuropharmacology—the fifth generation of progres

Cited by

Sorted by citations

Items 101–179 of 179

Metadata

Authors
Abi-Dargham, A., & Laruelle, M.
Affiliations
New York State Psychiatric Institute (US)
Venue
European Psychiatry
Published
2005-01
Volume
20
Issue
1
Pages
15-27
ISSN
  • 0924-9338 (ISSN-L)
  • 1778-3585
OpenAlex
W2029915913
Cited by
179
References
175
Citations by year
2026: 6 · 2025: 5 · 2024: 5 · 2023: 5 · 2022: 3 · 2021: 1 · 2020: 6 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 8 · 2015: 7 · 2014: 14 · 2013: 10 · 2012: 17
FWCI
1.46
Type
journal article
Language
en
Open access
closed
Locations
  • European Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5k08mh001594-05, 5k02mh064178-03)
  • National Institute of Mental Health (K02 MH064178-01A2, K02MH01603-01, K02MH001603, K08 MH01594-01)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
atypical antipsychotics, schizophrenia, dopaminergic system, dopamine D2 receptor antagonism, dopamine D1 receptor, striatal dopamine, NMDA receptor, glutamatergic neurotransmission, extrapyramidal symptoms, typical antipsychotics, prefrontal dopamine, neuroimaging
MeSH terms
Brain, Dopamine, Humans, Schizophrenia, Antipsychotic Agents, Tomography, Emission-Computed, Single-Photon, N-Methylaspartate, Receptors, Dopamine D1, Glutamic Acid, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review